SBP-1750 is a potent, orally active autophagy inhibitor with a dual mechanism of action. It functions as a kinase inhibitor, strongly suppressing ULK1 (IC50 = 8 nM) and ULK2 (IC50 = 50 nM) activity, while simultaneously inducing the degradation of ATG13 (EC50 = 114 nM). This dual-targeting approach effectively blocks autophagic flux and induces cell death, exhibiting significant efficacy particularly against KRAS-mutant cancers such as pancreatic and lung cancers.

ULK2:50 nM, ULK1:8 nM